The Norwegian Immunotherapy in Multiple Myeloma Study

Determine the real-world overall response rates (ORR)

Time frame: From date of treatment start and until date of first documented progression or start of next line of therapy, whichever came first, assessed up to ten years.

Determine real-world progression-free survival (PFS)

Time frame: From date of treatment start and until date of first documented progression or death, whichever came first, , assessed up to ten years.

Determine real-world time-to-next treatment (TTNT)

Time frame: From date of treatment start and until date of start of next treatment, assessed up to ten years.

Determine real-world overall survival (OS)

Time frame: From date of treatment start and until death, assessed up to ten years.

Describe the frequency and grading of adverse events of special interest (AESI), defined as described below.

* Cytokine release syndrome (CRS) (ASTCT grade 1-5), * Infections (CTCAE grade 1-5) * Neurological adverse events (including, but not limited to, ICANS, peripheral sensory and/or motor neuropathy, neurocognitive and hypokinetic movement disorder) (CTCAE 5.0. grade 1-5). * Immune effector cell-associated hematotoxicity (ICAHT) (EHA/EBMT Consensus Grading 1-4)27 * Secondary malignancies, dysgeusia, skin- and nail adverse events, pain, hemophagocytic lymphohistiocytosis (HLH) and tumor lysis syndrome (CTCAE grade 1-5)

Time frame: From date of treatment start until the date of start of next line of treatment or death, whichever came first, assessed up to 10 years

Frequency and grading of all other adverse events occurring during treatment according to CTCAE 5.0 (only grade 3 or higher will be reported).

Time frame: From start of treatment and until start of next treatment or death, assessed up to ten years.

Describe the microbiological pattern (positive cultures/PCR) of infections during treatment.